Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: Comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter

Circulation

Volumn 101, Issue 18, 2000, Pages 2193-2199

  Eizema, Karin ^b   Fechner, Henry ^b   Bezstarosti, Karel ^b   Schneider Rasp, Sonja ^b   Van Der Laarse, Arnoud ^b   Wang, Haili ^b   Schultheiss, Heinz Peter ^b   Poller, Wolfgang C ^b   Lamers, Jos M J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NONE

Author keywords

Adenovirus; Atrial natriuretic factor; Calcium; Endothelin; Gene therapy; Sarcoplasmic reticulum

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COMPLEMENTARY DNA; ENDOTHELIN 1; PHOSPHOLAMBAN;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE THERAPY; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE CONTRACTION; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT;

EID: 0034624993     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.18.2193     Document Type: Article

References (31)

1. Francis GS. Cohn JN. Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J. 1990;4:3068-3075.
2. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
3. 2+ ATPase gene. Circ Res. 1992;71:9-17.
4. Arai M, Matsui H, Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res. 1994; 74:555-564.
5. Hasenfuss G, Just H. Myocardial phenotype changes in heart failure: cellular and subcellular changes and their functional significance. Br Heart J. 1994;72:510-517.
6. Simmerman HKB, Jones LR. Phospholamban: protein structure, mechanism of action and role in cardiac function. Physiol Rev. 1998; 78:921-947.
7. Koss KL, Grupp IL, Kranias EG. The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility. Basic Res Cardiol. 1997;92(suppl 1): 17-24.
8. 2+ ATPase overexpressing by adenovirus mediated gene transfer and in transgenic mice. Cardiovasc Res. 1998;37:360-366.
9. 2+-ATPase. Circ Res. 1997;81:145-153.
10. Franz WM, Rothmann T, Frey N, et al. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc Res. 1997;35:560-566.
11. Inesi G, Lewis D, Sumbilla C, et al. Cell-specific promoter in adenovirus vector for transgenic expression of SERCA1 ATPase in cardiac myocytes. Am J Physiol. 1998;274:C645-C653.
12. Shubeita HE, McDonough PM, Harris AN, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for cell hypertrophy. J Biol Chem. 1990;265:20555-20562.
13. 2+ ATPase promoter activity during endothelin-1 induced hypertrophy of cultured rat cardiomyocytes. Cardiovasc Res. 1998; 37:503-514.
14. Choukroun G, Hajjar R, Kyriakis JM, et al. Role of stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J Clin Invest. 1998;102:1311-1320.
15. Shanahan CM, Weissberg PL, Metcalfe JC. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ Res. 1993;73:193-204.
16. Poller W, Schneider-Rasp S, Liebert U, et al. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Ther. 1996;3:521-530.
17. Gambaryan S, Wagner C, Smolenski A, et al. Cyclic AMP-stimulated renin release from rat isolated perfused kidney, microdissected glomeruli, and isolated juxtaglomerular cells is inhibited by endogenous or overexpressed cGMP-dependent protein kinases. Proc Natl Acad Sci U S A. 1998;95:9003-9008.
18. Eizema K, Van Heugten HAA, Bezstarosti K, et al. In vitro analysis of SERCA2 gene regulation in hypertrophic cardiomyocytes and increasing transfection efficiency by gene-gun biolistics. Ann NY Acad Sci. 1999;874:111-124.
19. Eizema K, Van Heugten HAA, Bezstarosti K, et al. SERCA2 and ANF promoter-activity studies in hypertrophic cardiomyocytes using liposome-, gene gun- and adenovirus-mediated gene transfer. In: Takeda N, Nagano M, Dhalla NS, eds. The Hypertrophied Heart. Boston, Mass: Kluwer Academic Publishing; In press.
20. Decock JB, Gillespie-Brown J, Parker PJ, et al. Classical, novel and atypical isoforms of PKC stimulate ANF and TRE/AP-1 regulated promoter activity in ventricular cardiomyocytes. FEBS Lett. 1994; 356:275-278.
21. Van Heugten HAA, Bezstarosti K, Dekkers DHW, et al. Homologous desensitization of the endothelin-1 receptor evoked phosphoinositide response in cultured neonatal rat cardiomyocytes. J Mol Cell Cardiol. 1994;25:41-52.
22. Lamers JMJ, Duncker DJ, Bezstarosti K, et al. Increased activity of the sarcoplasmic reticular calcium pump in porcine stunned myocardium. Cardiovasc Res. 1993;27:520-524.
23. 2+ uptake activity and isolation of vesicles with improved calcium uptake activity. Mol Cell Biochem. 1990;99:41-52.
24. Ince C, van Dissel JT, Diesselhoff MMC. A Teflon culture dish for high-magnification microscopy and measurements in single cells. Pflugers Arch. 1985;403:240-244.
25. 2-incubator for use on a microscope. J Immunol Methods. 1983;60: 269-275.
26. 2+ sensitivity of SERCA2a in failing human myocardium due to reduced serine-16 phospholamban phosphorylation. J Mol Cell Cardiol. 1999;31: 479-491.
27. 2+-ATPase activity and cardiac myocyte contractility. Circulation. 1999;100:974-980.
28. 2+. Am J Physiol. 1996;271:C391-C397.
29. Knowlton KR, Rockman HA, Itani M, et al. Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophic ventricular myocardium. J Clin Invest. 1995;96:1311-1318.
30. Hajjar RJ, Schmidt U, Matsui T, et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci U S A. 1998;95:5251-5256.
31. v-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 1999;6:1520-1535.